Weight-loss medications like Ozempic, Mounjaro, and Wegovy have revolutionized obesity treatment, offering significant reductions in body weight and providing additional health benefits, including a lower risk of heart attacks, strokes, and kidney disease. These drugs have also been linked to a 17 percent lower overall cancer risk, with notable decreases in ovarian, womb, and certain brain tumors. However, a comprehensive study involving nearly 44,000 overweight and obese individuals, tracked for up to ten years, has raised concerns about a potential link to kidney cancer.

Published in JAMA Oncology, the study revealed that patients on these slimming injections were approximately one-third more likely to develop kidney cancer compared to non-users, with the risk being highest among those under 65 and individuals who were overweight. While overall cancer diagnoses were lower in jab users (891 cases vs. 1,022 in non-users), kidney cancer saw 83 cases among users against 58 in non-users. Kidney cancer is a